EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieÄquivalenzstudieOpen Access · CC BY-NC-ND 4.0

A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder

Qian Zhao, Bingbing Fu, Nan Lyu, Xiangdong Xu, Guangbiao Huang, Yunlong Tan, Xiufeng Xu, Xuehua Zhang, Xueyi Wang, Zhiqiang Wang, Keqing Li, ZhenYu Hu und 21 weitere

Journal of Affective Disorders · 2023

DOI: 10.1016/j.jad.2023.02.067 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2023. Verfasst von Qian Zhao und 32 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing An…. Hauptthemen laut MEDLINE: Major Depressive Disorder. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Desvenlafaxine and duloxetine are selective serotonin and norepinephrine reuptake inhibitors. Their efficacy has not been directly compared using statistical hypotheses. This study evaluated the non-inferiority of desvenlafaxine extended-release (XL) to duloxetine in patients with major depressive disorder (MDD). METHODS: In this study, 420 adult patients with moderate-to-severe MDD were enrolled and randomly assigned (1:1) to receive 50 mg (once daily [QD]) of desvenlafaxine XL (n = 212) or 60 mg QD of duloxetine (n = 208). The primary endpoint was evaluated using a non-inferiority comparison based on the change from baseline to 8 weeks in the 17-item Hamilton Depression Rating Scale (HAMD17) total score. Secondary endpoints and safety were evaluated. RESULTS: Least-squares mean change in HAM-D17 total score from baseline to 8 weeks was -15.3 (95% confidence interval [CI]: -17.73, -12.89) in the desvenlafaxine XL group and - 15.9 (95% CI, -18.44, -13.39) in the duloxetine group. The least-squares mean difference was 0.6 (95% CI: -0.48, 1.69), and the upper boundary of 95% CI was less than the non-inferiority margin (2.2). No significant between-treatment differences were found in most secondary efficacy endpoints. The incidence of the most common treatment-emergent adverse events (TEAEs) was lower for desvenlafaxine XL than for duloxetine for nausea (27.2% versus 48.8%) and dizziness (18.0% versus 28.8%). LIMITATIONS: A short-term non-inferiority study without a placebo arm. CONCLUSIONS: This study demonstrated that desvenlafaxine XL 50 mg QD was non-inferior to duloxetine 60 mg QD in efficacy in patients with MDD. Desvenlafaxine had a lower incidence of TEAEs than duloxetine did.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderAdultHumansDuloxetine HydrochlorideDesvenlafaxine SuccinateAntidepressive AgentsDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

17-item Hamilton Depression Rating ScaleDesvenlafaxineDuloxetineMajor depressive disorderNon-inferiority

Substanzen

Duloxetine HydrochlorideDesvenlafaxine SuccinateAntidepressive Agents

Autor:innen und Institutionen

  • Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
  • Department of Psychiatry, The Fourth People's Hospital of Urumqi, Urumqi, China.
  • Department of Psychiatry, Huzhou Third Municipal Hospital, Huzhou, China.
  • Psychiatry Research Center, Beijing Huilongguan Hospital, Beijing, China.
  • Department of Psychiatry, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
  • Hunan Brain Hospital (Hunan Second Municipal Hospital), Changsha, China.

Zitieren

APA

Zhao, Q., Fu, B., Lyu, N., Xu, X., Huang, G., Tan, Y., Xu, X., Zhang, X., Wang, X., Wang, Z., Li, K., Hu, Z., Li, H., He, H., Li, S., Zhao, J., He, R., Guo, H., Li, Y., …, & Wang, G. (2023). A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2023.02.067

Vancouver

Zhao Q, Fu B, Lyu N, Xu X, Huang G, Tan Y, et al. A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder. Journal of Affective Disorders. 2023. doi:10.1016/j.jad.2023.02.067

BibTeX
@article{Zhao2023,
  author = {Zhao, Qian and Fu, Bingbing and Lyu, Nan and Xu, Xiangdong and Huang, Guangbiao and Tan, Yunlong and Xu, Xiufeng and Zhang, Xuehua and Wang, Xueyi and Wang, Zhiqiang and Li, Keqing and Hu, ZhenYu and Li, Hengfen and He, Hongbo and Li, Shuang and Zhao, Jingyuan and He, Ruifeng and Guo, Hua and Li, Yi and Li, Lehua and Yang, Chuang and Zou, Shaohong and Wei, Bo and Wang, Wenqiang and Chen, Ce and Lu, Zheng and He, Shunqiang and Wang, Qian and Zhao, Jinghua and Pan, Xiaoyue and Pan, Zhenyu and Li, Junqing and Wang, Gang},
  title = {A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder},
  journal = {Journal of Affective Disorders},
  year = {2023},
  doi = {10.1016/j.jad.2023.02.067}
}
Kostenlos starten →